Evidence map›Paper›PMID 39487946›Full record

ArticleNeurology and therapy2025

Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection.

Alessandro Martorana, Chiara Giuseppina Bonomi, Martina Gaia Di Donna, Caterina Motta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alessandro MartoranaMemory Clinic and Neurodegenerative Dementia Research Unit, University Hospital Policlinico Tor Vergata, University of Rome "Tor Vergata", Viale Oxford, 81, 00133, Rome, Italy. martorana@med.uniroma2.it.ORCID http://orcid.org/0000-0001-8456-4169
Chiara Giuseppina BonomiMemory Clinic and Neurodegenerative Dementia Research Unit, University Hospital Policlinico Tor Vergata, University of Rome "Tor Vergata", Viale Oxford, 81, 00133, Rome, Italy.
Martina Gaia Di DonnaMemory Clinic and Neurodegenerative Dementia Research Unit, University Hospital Policlinico Tor Vergata, University of Rome "Tor Vergata", Viale Oxford, 81, 00133, Rome, Italy.
Caterina MottaMemory Clinic and Neurodegenerative Dementia Research Unit, University Hospital Policlinico Tor Vergata, University of Rome "Tor Vergata", Viale Oxford, 81, 00133, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lecanemab (Leqembi

Indexed as

Alzheimer’s diseaseImmunotherapyLecanemab

Identifiers

PMID39487946
PMCPMC11762048

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.